Product image of Iodure (123i) De Sodium Curiumpharma (Sodium Iodide (123 I)) supplied by GNH India

Iodure (123i) De Sodium Curiumpharma

Active Ingredient:
Sodium Iodide (123 I)
Origin:
EU

Iodure (123i) De Sodium Curiumpharma (Sodium Iodide (123 I))

Sodium Iodide, the active ingredient in Iodure (123i) De Sodium Curiumpharma, is a radiopharmaceutical presented as a sterile solution for intravenous use. It is used for diagnostic imaging of the thyroid and related tissues in patients requiring functional assessment.

GNH India supplies Iodure (123i) De Sodium Curiumpharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Curium Netherlands B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Iodure (Sodium Iodide I‑123) is employed in nuclear medicine to visualize thyroid tissue and assess its function.

  • Thyroid imaging: Provides high‑resolution scintigraphic images of thyroid anatomy and iodine uptake.
  • Evaluation of thyroid function: Quantifies glandular activity to differentiate hyper‑ and hypothyroidism.
  • Detection of thyroid cancer metastases: Identifies metastatic lesions by highlighting iodine‑avid tissue beyond the thyroid gland.

How It Works

  • Sodium Iodide (I‑123) is taken up by thyroid follicular cells via the sodium‑iodide symporter. The radionuclide emits gamma photons that are captured by a gamma camera, producing detailed images of thyroid tissue distribution and functional activity without significantly altering thyroid hormone synthesis.

Side Effects

Adverse reactions may occur following intravenous administration of Iodure.

Common Side Effects

  • Nausea: mild, transient feeling of stomach upset.
  • Headache: mild to moderate, usually resolves spontaneously.
  • Warmth or flushing: brief sensation at the injection site.
  • Injection site discomfort: mild pain or irritation.
  • Transient hypotension: slight drop in blood pressure shortly after dosing.

Serious or Rare Side Effects

  • Allergic reaction: rash, itching, or anaphylaxis requiring immediate medical attention.
  • Severe hypotension: marked blood pressure decrease needing intervention.
  • Radiation‑induced thyroiditis: inflammation of the thyroid gland.
  • Hematologic abnormalities: rare changes in blood counts.
  • Pulmonary embolism: extremely rare, presenting with respiratory distress.

Precautions & Warnings

Prior to administration, clinicians should evaluate patient‑specific factors and follow radiation safety guidelines.

  • Pregnancy: use only if the diagnostic benefit outweighs potential fetal radiation exposure.
  • Breastfeeding: consider temporary cessation of nursing or assess infant risk.
  • Renal function: assess because impaired clearance may affect radiation dose.
  • Thyroid status: avoid in untreated hyperthyroidism unless specifically indicated.
  • Radiation safety: adhere to institutional protocols for handling and disposal of radioactive material.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Sodium Iodide I‑123 may interact with other agents that affect iodine metabolism or cardiovascular stability.

Major Interactions (Avoid)

  • Iodine‑containing contrast agents: can interfere with tracer uptake and imaging interpretation.
  • Thyroid hormone therapy: may alter iodine uptake, reducing diagnostic accuracy.
  • Antithyroid drugs: can diminish tracer accumulation in the thyroid.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may blunt heart‑rate response during stress testing.
  • ACE inhibitors: monitor blood pressure for additive hypotensive effects.
  • Diuretics: observe fluid balance and renal function during administration.

Frequently Asked Questions

Iodure (123i) contains Sodium Iodide I‑123 and is used as a diagnostic radiopharmaceutical for thyroid imaging, evaluation of thyroid function, and detection of metastatic thyroid cancer. The tracer is administered intravenously and imaged with a gamma camera to provide functional information about iodine‑avid tissues.

Sodium Iodide I‑123 is actively transported into thyroid follicular cells by the sodium‑iodide symporter. Once inside, the radionuclide emits gamma radiation that is captured by a gamma camera, producing images that reflect the distribution and activity of thyroid tissue without significantly affecting hormone production.

The administered activity of Iodure (123i) is determined by the prescribing physician based on the patient’s age, weight, clinical indication, and imaging protocol. Dosage is individualized and should follow local nuclear medicine guidelines and regulatory requirements.

Pregnancy and breastfeeding are considered relative contraindications because the radiotracer delivers ionising radiation. Use is permitted only when the diagnostic benefit outweighs potential risks to the fetus or infant, and appropriate radiation safety measures should be applied.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Iodure (123i) uses I‑123, which emits gamma photons ideal for high‑resolution imaging and has a shorter half‑life than I‑131, resulting in lower radiation dose. Compared with technetium‑99m pertechnetate, I‑123 provides better thyroid uptake specificity, making it preferred for detailed functional studies.

Iodure (123i) must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The product should be kept in its original container until use and handled in accordance with radiopharmaceutical safety protocols.

The radiopharmaceutical is administered intravenously by a qualified healthcare professional. The injection is typically performed in a controlled nuclear medicine suite, and imaging is conducted shortly after administration according to the prescribed protocol.

Serious risks include allergic reactions ranging from rash to anaphylaxis, severe hypotension, radiation‑induced thyroiditis, and rare hematologic abnormalities. Patients should be monitored during and after injection, and any adverse signs should be addressed promptly.

Patients with known hypersensitivity to iodine or radiopharmaceutical components, untreated hyperthyroidism (unless specifically indicated), pregnant or breastfeeding women where the benefit does not outweigh risk, and individuals unable to comply with radiation safety measures should not receive Iodure (123i).

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sodium Iodide (123 I)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT